1. Home
  2. LQDA vs FORTY Comparison

LQDA vs FORTY Comparison

Compare LQDA & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • FORTY
  • Stock Information
  • Founded
  • LQDA 2004
  • FORTY 1985
  • Country
  • LQDA United States
  • FORTY Israel
  • Employees
  • LQDA N/A
  • FORTY N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • FORTY EDP Services
  • Sector
  • LQDA Health Care
  • FORTY Technology
  • Exchange
  • LQDA Nasdaq
  • FORTY Nasdaq
  • Market Cap
  • LQDA 1.9B
  • FORTY 2.3B
  • IPO Year
  • LQDA 2018
  • FORTY 1997
  • Fundamental
  • Price
  • LQDA $24.53
  • FORTY $137.45
  • Analyst Decision
  • LQDA Strong Buy
  • FORTY
  • Analyst Count
  • LQDA 9
  • FORTY 0
  • Target Price
  • LQDA $32.67
  • FORTY N/A
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • FORTY 341.0
  • Earning Date
  • LQDA 11-03-2025
  • FORTY 11-20-2025
  • Dividend Yield
  • LQDA N/A
  • FORTY 1.00%
  • EPS Growth
  • LQDA N/A
  • FORTY 15.06
  • EPS
  • LQDA N/A
  • FORTY 4.97
  • Revenue
  • LQDA $19,322,000.00
  • FORTY $2,889,481,000.00
  • Revenue This Year
  • LQDA $424.31
  • FORTY N/A
  • Revenue Next Year
  • LQDA $359.32
  • FORTY N/A
  • P/E Ratio
  • LQDA N/A
  • FORTY $28.39
  • Revenue Growth
  • LQDA 30.20
  • FORTY 8.58
  • 52 Week Low
  • LQDA $9.71
  • FORTY $77.50
  • 52 Week High
  • LQDA $29.94
  • FORTY $151.31
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 52.65
  • FORTY 53.05
  • Support Level
  • LQDA $22.05
  • FORTY $142.00
  • Resistance Level
  • LQDA $24.34
  • FORTY $148.00
  • Average True Range (ATR)
  • LQDA 1.26
  • FORTY 1.45
  • MACD
  • LQDA 0.10
  • FORTY -0.17
  • Stochastic Oscillator
  • LQDA 60.51
  • FORTY 30.98

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources, Michpal, ZAP Group, and Others. The majority of the company's revenue comes from Israel.

Share on Social Networks: